CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary ...
Phase 3
Seoul, Korea, Republic of and 125 other locations
adult subjects with CA125-associated, advanced recurrent epithelial ovarian, fallopian tube or peritoneal carcinoma (FIGO Stage III/IV) with...
Phase 1, Phase 2
Seoul, Korea, Republic of and 5 other locations
followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian ...
Phase 3
Seoul, Korea, Republic of and 213 other locations
of alpelisib and olaparib compared with single agent cytotoxic chemotherapy in patients with platinum resistant or refractory high-grade serous ovarian...
Phase 3
Seoul, Korea, Republic of and 93 other locations
Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy....
Phase 3
Seoul, Korea, Republic of and 176 other locations
This is a randomized phase II study of secondary cytoreductive surgery (CRS) in patients with relapsed ovarian cancer who have prog...
Phase 2
Seoul, Korea, Republic of
A Phase 2/3 study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer...
Phase 2, Phase 3
Seoul, Korea, Republic of and 38 other locations
To evaluate the efficacy and safety of JPI-547, a PARP/TNKS dual inhibitor in Platinum-resistant, advanced/relapsed ovarian cancer ...
Phase 2
Gyeonggi-do, Korea, Republic of
This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and phar...
Phase 1
Seoul, Korea, Republic of and 23 other locations
in combination with pembrolizumab versus protocol-specific Investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian...
Phase 3
Seoul, Korea, Republic of and 117 other locations
Clinical trials
Research sites
Resources
Legal